Auxilart and Renzoku Biologics Partner to Advance Biopharmaceutical Process Development Through Mathematical Modeling

Tokyo, Japan -- December 2025 -- Auxilart Co., Ltd., a University of Tokyo spinout specializing in mathematical modeling and simulation for pharmaceutical manufacturing, today announced a collaboration with Renzoku Biologics Inc. to develop mathematical models aimed at accelerating biopharmaceutical manufacturing process development.

The partnership will combine Auxilart’s modeling and simulation technology with Renzoku Biologics’ advanced biomanufacturing capabilities to support the development of an Advanced Biomanufacturing Factory, integrating digital modeling into real-world process development.

Biopharmaceutical process development has become increasingly complex as product modalities evolve and quality requirements continue to rise. In particular, biological processes such as cell culture require extensive experimentation to manage biological variability and generate reliable data. CDMOs (Contract Development and Manufacturing Organizations that develop and manufacture drugs on behalf of other pharma and biotech firms) across the industry have accordingly been focusing on building rapid and reliable process development capabilities through the systematic accumulation of experimental knowledge and expertise.

By combining experimental work with mathematical modeling and simulation, the two companies aim to improve development efficiency, deepen process understanding, and reduce the number of experimental iterations required during development. Maximizing the value of experimentally derived insights through simulation to further enhance development efficiency has become a critical factor in strengthening competitive advantage going forward.

Under the collaboration, Auxilart will develop mathematical models and conduct simulation analyses, while Renzoku Biologics will perform experimental studies and generate process data within operational manufacturing environments. The joint effort will focus initially on modeling cell culture processes to enable more efficient exploration of operating conditions and improved process understanding.

Looking further ahead, both companies aim to extend this modeling technology beyond cell culture process development to encompass cell line screening and downstream processing, enabling more rapid progression from process design through scale-up.

“This collaboration represents an important step toward implementing model-driven process development in biopharmaceutical manufacturing,” said Junu Kim, CEO of Auxilart. “Biopharmaceutical manufacturing has long been supported by the rich accumulation of experimental expertise and knowledge built up over many years. Through this collaboration, we aim to formalize and leverage that expertise in the form of structured mathematical models, improving development speed, reproducibility, and scalability. By uniting the strengths of both organizations, we look forward to advancing digitalization in biopharmaceutical manufacturing and contributing to the establishment of next-generation biomanufacturing infrastructure.”

Hitoshi Kuboniwa, President and CEO of Renzoku Biologics, added: “Renzoku Biologics is committed to implementing advanced manufacturing technologies that enable the next generation of biopharmaceutical production. By working with Auxilart, we expect to introduce model-driven approaches from the early stages of process development, enabling more efficient development and more flexible manufacturing. Going forward, we also aim to leverage this collaboration to strengthen our competitive positioning in the global market. The collaboration reflects a broader shift within the pharmaceutical industry toward integrating digital technologies and modeling approaches into bioprocess development to accelerate innovation and improve manufacturing performance.”

About Auxilart

Auxilart is a Tokyo-based technology company focused on accelerating research and development processes through advanced modeling and simulation technologies derived from more than a decade of research at the University of Tokyo. Its mathematical modeling approach enables high-accuracy digital simulations using significantly less experimental data than traditional AI-driven approaches. By replacing a portion of physical experiments with digital simulation, Auxilart contributes to meaningful reductions in both development costs and timelines, helping pharmaceutical companies improve process understanding and accelerate time-to-market.

Since its founding in 2023, Auxilart has delivered modeling and simulation services to a diverse range of clients, primarily leading domestic and international pharmaceutical companies.

Company: https://auxilart.com/

About Renzoku Biologics

Renzoku Biologics develops advanced manufacturing technologies and provides CDMO services for next-generation biopharmaceutical production. The company focuses on integrating advanced manufacturing approaches, including continuous production technologies, to deliver more flexible and efficient manufacturing solutions compared with traditional batch-based systems.

Renzoku Biologics provides end-to-end support spanning research and development, manufacturing process development, and GMP manufacturing, contributing to the acceleration of biopharmaceutical development and the advancement of manufacturing capabilities. Through the development of a next-generation biopharmaceutical manufacturing platform, the company is driving the evolution of biopharmaceutical manufacturing in the global market.

Company: https://renzoku-biologics.com/

Executive Profiles

Junu Kim -- Chief Executive Officer, Auxilart Co., Ltd.

Co-founder and CEO of Auxilart. Leads technical delivery of mathematical modeling solutions for pharmaceutical manufacturing clients, with hands-on expertise in process simulation and scale-up optimization. Has directed projects across biopharma dev teams, including work with global Pharma and CDMOs.

Hitoshi Kuboniwa -- Representative Director, President and CEO, Renzoku Biologics Inc.

Hitoshi Kuboniwa spent 37 years at Chugai Pharmaceutical Co., Ltd., where he held a wide range of roles spanning exploratory research and business development. He subsequently served as Head of the Pharmaceutical Sciences Laboratory, Head of Supply Chain, Head of the Pharmaceutical Division, and ultimately as Senior Executive Officer overseeing pharmaceutical operations. Following his retirement, he has taken on advisory roles for the Japan Bioindustry Association (JBA), the Japan Agency for Medical Research and Development (AMED), and various government committees.

Media Contact

Auxilart Co., Ltd.
Established: July 19, 2023
CEO: Junu Kim
Headquarters: Room 3-62, Gate Cross HONGO 3F, 4-1-16 Yushima, Bunkyo-ku, Tokyo, 113-0034, Japan

Contact Person: Kay (Keisuke) Okita
LinkedIn: linkedin.com/company/auxilart-co-ltd/
Email: information@auxilart.com